Literature DB >> 34918416

Toxicity of induction chemotherapy in head and neck cancer: The central role of skeletal muscle mass.

Alexane Lere-Chevaleyre1, Maureen Bernadach2, Céline Lambert3, Lucie Cassagnes4, Mathilde Puechmaille1, Thierry Mom1, Laurent Gilain1, Michel Lapeyre5, Yves Boirie6,7, Julian Biau5, Nicolas Saroul1,6.   

Abstract

BACKGROUND: To assess the impact of nutritional status on tolerance to induction chemotherapy by docetaxel, cisplatin and 5-fluorouracil (ICT) in head and neck cancer (HNC).
METHODS: Ninety-two HNC patients were included. Toxicity was assessed according to common terminology criteria for adverse events. Nutritional status was assessed by body mass index (BMI), serum albumin, nutritional risk index (NRI), and CT scan (skeletal muscle mass index [SMI] at the first lumbar vertebral level).
RESULTS: Before treatment, average BMI was 22.7 ± 4.6 kg/m2 , serum albumin 38.7 ± 5.8 g/L, NRI 97.6 ± 10.6, and SMI 36.4 ± 7.9 cm2 /m2 . After treatment, BMI was 23 ± 4.5, serum albumin 30.2 ± 7.1, and NRI 88.1 ± 9.2. During ICT, 52 (62%) patients developed at least one toxicity ≥ Grade 3. Pre-treatment SMI was the only predictive factor of toxicity irrespective of BMI (p = 0.04).
CONCLUSION: Low skeletal muscle mass is a predictive factor of toxicity to ICT in HNC.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  body composition; chemo-toxicity; head and neck cancer; muscular mass; nutritional status; taxotere-platine-fluorouracil

Mesh:

Substances:

Year:  2021        PMID: 34918416     DOI: 10.1002/hed.26954

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Sex-Specific Cut-Off Values for Low Skeletal Muscle Mass to Identify Patients at Risk for Treatment-Related Adverse Events in Head and Neck Cancer.

Authors:  Aniek T Zwart; Wolf Pörtzgen; Irene van Rijn-Dekker; Grigory A Sidorenkov; Rudi A J O Dierckx; Roel J H M Steenbakkers; Inge Wegner; Anouk van der Hoorn; Geertruida H de Bock; Gyorgy B Halmos
Journal:  J Clin Med       Date:  2022-08-09       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.